TY - JOUR
T1 - Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma
AU - Chiou, Shih Hwa
AU - Yu, Cheng Chia
AU - Huang, Chi Yang
AU - Lin, Shu Chun
AU - Liu, Chung Ji
AU - Tsai, Tung Hu
AU - Chou, Shiu Huey
AU - Chien, Chian Shiu
AU - Ku, Hung Hai
AU - Lo, Jeng Fan
PY - 2008/7/1
Y1 - 2008/7/1
N2 - Purpose: Oral squamous cell carcinoma (OSCC), like many solid tumors, contains a heterogeneous population of cancer cells. Recent data suggest that a rare subpopulation of cancer cells, termed cancer stem cells (CSC), is capable of initiating, maintaining, and expanding the growth of tumor. Identification and characterization of CSC from OSCC facilitates the monitoring, therapy, or prevention of OSCC. Experimental Design: We enriched oral cancer stem-like cells (OC-SLC) through sphere formation by cultivating OSCC cells from established OSCC cell lines or primary cultures of OSCC patients within defined serum-free medium. Differential expression profile of sternness genes between enriched OC-SLC and parental OSCC was elucidated. Furthermore, immunohistochemical staining of sternness markers on OSCC patient tissues was examined to evaluate the association between sternness genes and prognosis of OSCC. Results: Enriched OC-SLC highly expressed the stem/progenitor cell markers and ABC transporter gene (Oct-4, Nanog, CD117, Nestin, CD133, and ABCG2) and also displayed induced differentiation abilities and enhanced migration/invasion/malignancy capabilities in vitro and in vivo. Elevated expression of CD133 was shown in the enriched OC-SLC from OSCC patients' tumors. Positive correlations of Oct-4, Nanog, or CD133 expression on tumor stage were shown on 52 OSCC patient tissues. Kaplan-Meier analyses exhibited that Nanog/Oct-4/CD133 triple-positive patients predicted the worst survival prognosis of OSCC patients. Conclusion: We enriched a subpopulation of cancer stem-like cell from OSCC by sphere formation. The enriched OC-SLC possesses the characteristics of both stem cells and malignant tumors. Additionally, expression of sternness markers (Nanog/Oct-4/CD133) contradicts the survival prognosis of OSCC patients.
AB - Purpose: Oral squamous cell carcinoma (OSCC), like many solid tumors, contains a heterogeneous population of cancer cells. Recent data suggest that a rare subpopulation of cancer cells, termed cancer stem cells (CSC), is capable of initiating, maintaining, and expanding the growth of tumor. Identification and characterization of CSC from OSCC facilitates the monitoring, therapy, or prevention of OSCC. Experimental Design: We enriched oral cancer stem-like cells (OC-SLC) through sphere formation by cultivating OSCC cells from established OSCC cell lines or primary cultures of OSCC patients within defined serum-free medium. Differential expression profile of sternness genes between enriched OC-SLC and parental OSCC was elucidated. Furthermore, immunohistochemical staining of sternness markers on OSCC patient tissues was examined to evaluate the association between sternness genes and prognosis of OSCC. Results: Enriched OC-SLC highly expressed the stem/progenitor cell markers and ABC transporter gene (Oct-4, Nanog, CD117, Nestin, CD133, and ABCG2) and also displayed induced differentiation abilities and enhanced migration/invasion/malignancy capabilities in vitro and in vivo. Elevated expression of CD133 was shown in the enriched OC-SLC from OSCC patients' tumors. Positive correlations of Oct-4, Nanog, or CD133 expression on tumor stage were shown on 52 OSCC patient tissues. Kaplan-Meier analyses exhibited that Nanog/Oct-4/CD133 triple-positive patients predicted the worst survival prognosis of OSCC patients. Conclusion: We enriched a subpopulation of cancer stem-like cell from OSCC by sphere formation. The enriched OC-SLC possesses the characteristics of both stem cells and malignant tumors. Additionally, expression of sternness markers (Nanog/Oct-4/CD133) contradicts the survival prognosis of OSCC patients.
UR - http://www.scopus.com/inward/record.url?scp=48249105531&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-07-4404
DO - 10.1158/1078-0432.CCR-07-4404
M3 - Article
C2 - 18593985
AN - SCOPUS:48249105531
SN - 1078-0432
VL - 14
SP - 4085
EP - 4095
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 13
ER -
